Safety and immunogenicity of a nicotine conjugate vaccine in current smokers
Safety and immunogenicity of a nicotine conjugate vaccine in current smokers
复制标题
DOI：
10.1016/j.clpt.2005.08.007
复制
发表时间：
2005-11-01
影响因子：
6.7
通讯作者：
Pentel, PR
中科院分区：
文献类型：
--
作者：
Hatsukami, DK;Rennard, S;Pentel, PR
免疫疗法是治疗尼古丁成瘾的一种新型潜在疗法。本研究的目的是评估尼古丁结合疫苗 NicVAX 的安全性和免疫原性及其对吸烟行为的影响。吸烟者 (N = 68) 被招募参加一项不间断治疗研究，并被分配接受 3 剂尼古丁疫苗（50、100 或 200 μg）或安慰剂中的 1 剂。他们在第 0、28、56 和 182 天进行注射，并进行为期 38 周的监测。结果表明尼古丁疫苗安全且耐受性良好。疫苗的免疫原性与剂量相关（P
Immunotherapy is a novel potential treatment for nicotine addiction. The aim of this study was to assess the safety and immunogenicity of a nicotine conjugate vaccine, NicVAX, and its effects on smoking behavior. Smokers (N = 68) were recruited for a noncessation treatment study and assigned to 1 of 3 doses of the nicotine vaccine (50, 100, or 200 mu g) or placebo. They were injected on days 0, 28, 56, and 182 and monitored for a period of 38 weeks. Results showed that the nicotine vaccine was safe and well tolerated. Vaccine immunogenicity was dose-related (P